Roche (RHHBY), whose Vabysmo is expected to compete against high-dose Eylea if the latter gets approved, is trading in positive ground in afternoon trading in New York after Regeneron Pharmaceuticals (REGN) announced that the FDA has issued a Complete Response Letter, or CRL, for the Biologics License Application, or BLA, for aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug
- Roche granted FDA clearance for additional Alzheimer’s disease CSF assays
- Biotech Alert: Searches spiking for these stocks today
- Rugonersen development halt may be positive of Ultragenyx’s GTX-102, says Stifel
- Sarepta announces FDA approval of Elevidys gene therapy for DMD